GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coegin Pharma (NGM:COEGIN) » Definitions » Debt-to-Revenue

Coegin Pharma (NGM:COEGIN) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Coegin Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Coegin Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Coegin Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr0.00 Mil. Coegin Pharma's annualized Revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Coegin Pharma Debt-to-Revenue Historical Data

The historical data trend for Coegin Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coegin Pharma Debt-to-Revenue Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Coegin Pharma Quarterly Data
Dec18 Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Coegin Pharma's Debt-to-Revenue

For the Biotechnology subindustry, Coegin Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coegin Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coegin Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Coegin Pharma's Debt-to-Revenue falls into.



Coegin Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Coegin Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Coegin Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Coegin Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Coegin Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Coegin Pharma (NGM:COEGIN) Business Description

Traded in Other Exchanges
N/A
Address
Birger Jarlsgatan 18 A, 4th Floor, Stockholm, SWE, 114 34
Coegin Pharma AB is a biotechnology company that focuses on the development of small molecule therapies for the treatment of inflammatory diseases such as cancer and kidney disease.

Coegin Pharma (NGM:COEGIN) Headlines

No Headlines